Entera Bio Ltd

Entera Bio Ltd Stock Forecast & Price Prediction

Live Entera Bio Ltd Stock (ENTX) Price
$1.67

1

Ratings

  • Buy 1
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$1.67

P/E Ratio

-5.65

Volume Traded Today

$8,616

Dividend

Dividends not available for ENTX

52 Week High/low

3.35/0.52

Entera Bio Ltd Market Cap

$61.5M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $ENTX ๐Ÿ›‘

Before you buy ENTX you'll want to see this list of ten stocks that have huge potential. Want to see if ENTX made the cut? Enter your email below

ENTX Summary

From what 1 stock analysts predict, the share price for Entera Bio Ltd (ENTX) might decrease by 100% in the next year. This is based on a 12-month average estimation for ENTX. Price targets go from $ to $. The majority of stock analysts believe ENTX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

ENTX Analyst Ratings

ENTX is a stock in Healthcare which has been forecasted to be worth $ as an average. On the higher end, the forecast price is $ USD by from Maxim Group and on the lower end ENTX is forecasted to be $ by from Maxim Group.

ENTX stock forecast by analyst

These are the latest 20 analyst ratings of ENTX.

Analyst/Firm

Rating

Price Target

Change

Date

Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

Nov 11, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

Oct 7, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

Sep 27, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

Aug 12, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

Jun 5, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

May 14, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

May 13, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Maintains

Apr 2, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

Dec 11, 2023
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

Sep 13, 2023
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

Sep 11, 2023
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

May 8, 2023
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

Apr 4, 2023
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

Mar 28, 2023
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Initiates

Sep 6, 2022
Kalpit Patel
B. Riley Securities

Buy

$5

Maintains

Jul 19, 2022

B. Riley Securities

Buy


Initiates

Jun 16, 2021

Aegis Capital

Buy


Initiates

Mar 22, 2021

Maxim Group

Buy


Initiates

Aug 3, 2018

ENTX Company Information

What They Do: Develops oral peptide replacement therapies.

Business Model: Entera Bio Ltd. focuses on creating innovative oral therapies for unmet medical needs, leveraging its proprietary N-Tab technology to enhance the stability and absorption of peptides. The company generates revenue through partnerships, research collaborations, and potential commercialization of its advanced product candidates, which target conditions like osteoporosis and obesity.

Other Information: The company's lead product, EB613, is entering Phase 3 trials and aims to provide an oral treatment for post-menopausal women with osteoporosis. Additional products in development include therapies for hypoparathyroidism and obesity, showcasing a diverse pipeline. Founded in 2009 and based in Jerusalem, Israel, Entera Bio's collaborations, such as with OPKO Biologics, could enhance its research capabilities and market reach.
ENTX
Entera Bio Ltd (ENTX)

When did it IPO

2018

Staff Count

17

Country

Israel

Sector/Industry

Healthcare/Biotechnology

CEO

Ms. Miranda J. Toledano M.B.A.

Market Cap

$61.5M

Entera Bio Ltd (ENTX) Financial Data

In 2023, ENTX generated $0 in revenue, which was a decrease of -100.00% from the previous year. This can be seen as a signal that ENTX's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$365,000

Revenue From 2021

$571,000

56.44 %
From Previous Year

Revenue From 2022

$134,000

-76.53 %
From Previous Year

Revenue From 2023

$0

-100.00 %
From Previous Year
  • Revenue TTM $99,000
  • Operating Margin TTM -7,192.9%
  • Gross profit TTM $0
  • Return on assets TTM -70.6%
  • Return on equity TTM -144.7%
  • Profit Margin 0.0%
  • Book Value Per Share 0.18%
  • Market capitalisation $61.5M
  • Revenue for 2021 $571,000
  • Revenue for 2022 $134,000
  • Revenue for 2023 $0
  • EPS this year (TTM) $-0.26

Entera Bio Ltd (ENTX) Latest News

News Image

Fri, 08 Nov 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Entera Bio Ltd. (NASDAQ: ENTX) announced its financial results and business updates for Q3 2024, reporting significant developments in oral peptides and small therapeutic proteins.

Why It Matters - Entera Bio's financial results and business updates may indicate performance trends and growth potential, influencing stock valuation and investment decisions.

News Image

Fri, 08 Nov 2024

Sentiment - NEGATIVE

Source - Zacks Investment Research

Summary - Entera Bio Ltd. (ENTX) reported a quarterly loss of $0.08 per share, exceeding the Zacks Consensus Estimate of a $0.05 loss.

Why It Matters - Entera Bio's larger-than-expected quarterly loss may indicate operational challenges, potentially impacting investor confidence and stock performance.

News Image

Wed, 25 Sep 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Entera Bio and OPKO Health announced positive topline PK/PD results from their collaboration on an oral dual agonist for obesity, utilizing OPKO's OXM analog and Entera's N-Tabโ„ข technology.

Why It Matters - The collaboration may lead to a groundbreaking obesity treatment, potentially increasing market share and revenues for Entera Bio and OPKO, influencing their stock performance positively.

News Image

Thu, 26 Sep 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Entera and OPKO Health report positive pharmacokinetic/pharmacodynamic results in their research for the first oral dual agonist GLP-1/glucagon peptide.

Why It Matters - Positive PK/PD results from Entera and OPKO Health suggest potential breakthroughs in obesity and diabetes treatments, possibly increasing market value and attracting investor interest.

News Image

Wed, 18 Sep 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Entera Bio Ltd. (ENTX) and argenex SE (ARGX) have been assessed for their performance relative to their sector in the current year. Further details on metrics were not provided.

Why It Matters - Comparative performance metrics indicate how Entera Bio Ltd. and argenex SE are faring against their peers, influencing investment decisions based on market trends and company viability.

News Image

Mon, 02 Sep 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Entera Bio Ltd. (ENTX) and Akebia Therapeutics (AKBA) have shown performance results compared to their sector in 2023, as detailed in the report.

Why It Matters - Performance comparisons reveal how ENTX and AKBA are faring against their sector, indicating investor sentiment, potential growth, or risks that may influence investment decisions.

...

ENTX Frequently asked questions

The highest forecasted price for ENTX is $ from at Maxim Group.

The lowest forecasted price for ENTX is $ from from Maxim Group

The ENTX analyst ratings consensus are 1 buy ratings, 0 hold ratings, and 0 sell ratings.